1315 Capital Backs USpharma Ltd. with Growth Equity Investment

1315 Capital Leads Growth Investment in Experic

October 29, 2024

Pharmaceuticals

Experic, a Cranbury, New Jersey-based CDMO and clinical trial supply services firm, received a growth capital investment led by 1315 Capital with participation from existing investors East Seattle Partners, Harro Höfliger Packaging Systems, Inc., and Kineticos Ventures. The capital will be used to enhance Experic’s manufacturing capabilities and accelerate its international expansion to better serve biopharmaceutical clients.

1315 Capital Invests in Primrose Bio

June 17, 2024

Biotechnology

1315 Capital, a Philadelphia-based healthcare-focused growth equity firm, made a significant equity investment in Primrose Bio to support development and commercial expansion of Primrose’s nucleic acid and protein manufacturing technologies. The funding will accelerate commercialization of the company’s Prima RNApols, Pfenex expression system, and PeliCRM carrier protein for therapeutics and vaccines.

CPS Capital Makes Growth Investment in PharmaSmart International

July 12, 2021

Medical Devices

Toronto-based private equity firm CPS Capital made a strategic growth investment in PharmaSmart International alongside the company’s existing management team. The financing (which included term debt from FirePower Capital and Nicola Wealth) will fund roll‑out of PharmaSmart’s PS-2000D health kiosk platform and accelerate expansion across Canada and the United States.

1315 Capital Provides Growth Financing to ProSciento

September 10, 2020

Healthcare Services

ProSciento, a San Diego–based specialty clinical research organization focused on NASH, diabetes and obesity, closed a growth financing round with healthcare investor 1315 Capital. The capital will support expansion of ProSciento's CRO operations and growth of its patient access solutions, including the NASH PASS registry.

GHO Capital Acquires Majority Stake in Sterling Pharma Solutions

February 28, 2019

Pharmaceuticals

GHO Capital has acquired a majority stake in Sterling Pharma Solutions alongside management. The investment will support Sterling's international expansion and accelerate growth of its specialist API development and GMP manufacturing capabilities from its UK base in Newcastle upon Tyne.

1315 Capital Acquires Biocoat, Inc.

January 16, 2019

Medical Devices

Philadelphia-based healthcare investment firm 1315 Capital has acquired Biocoat, Inc., a Horsham, Pennsylvania specialty manufacturer of hydrophilic biomaterial coatings for medical devices; the transaction closed on December 20, 2018. 1315 Capital's investment will provide expansion and growth capital to accelerate R&D, expand Biocoat's operating model, and support broader commercial efforts across neurovascular, cardiovascular, peripheral, and ophthalmic end markets.